Sasson 1999.
| Methods | Study design: Randomised cross‐over trial | |
| Participants |
Diagnosis: DSM‐III‐R panic disorder Method of diagnosis: not stated Age: M = 36, SD = 8 Sex: males = 6, females = 11 Location: Israel; setting unclear Co‐morbidities: patients were free of significant medical problems, mental retardation, psychosis, drug abuse, organic lesions and primary mood disorders Rescue medication: not stated |
|
| Interventions |
Participants were randomly assigned to either: (1) clomipramine arm (n = 17) Duration: 6 weeks Treatment Protocol: flexible dosage, range = 75 ‐ 200 mg, M = 140, SD = 52 (2) desipramine arm (n = 17) Duration: 6 weeks Treatment Protocol: flexible dosage, range = 50 ‐ 300 mg, M = 190, SD = 69 According to the cross‐over design, patients received placebo for 2 weeks; active treatment for 6 weeks; placebo for 2 weeks; switch to the other active treatment for 6 weeks. Data on the active treatment phases are provided together. |
|
| Outcomes |
Time points for assessment: baseline, every two weeks Outcomes: 1. Hamilton Rating Scale for Anxiety (HAMA) 2. NIMH Global Scales for anxiety, depression and impairment 3. Zung Anxiety Scale 4. State‐Trait Anxiety Inventory (STAI) 5. number of panic attacks |
|
| Notes |
Date of study: not stated Funding source: not stated Declarations of interest among the primary researchers: not stated. |
|
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | Quote: "randomized". |
| Allocation concealment (selection bias) | Unclear risk | No information provided. |
| Blinding of participants and personnel (performance bias) All outcomes | Unclear risk | Quote: "double blind". No further information provided. |
| Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | Quote: "double blind". No further information provided. |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | No missing outcome data. |
| Selective reporting (reporting bias) | Low risk | All outcomes were reported. |
| Other bias | Unclear risk | Sponsorship bias cannot be ruled out. |